A detailed history of Bank Of America Corp transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 412,745 shares of CGEM stock, worth $7.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
412,745
Previous 131,349 214.24%
Holding current value
$7.12 Million
Previous $2.24 Million 221.63%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$15.63 - $29.35 $4.4 Million - $8.26 Million
281,396 Added 214.24%
412,745 $7.2 Million
Q1 2024

May 15, 2024

SELL
$10.17 - $19.02 $41,320 - $77,278
-4,063 Reduced 3.0%
131,349 $2.24 Million
Q4 2023

Feb 14, 2024

BUY
$7.89 - $10.23 $912,273 - $1.18 Million
115,624 Added 584.31%
135,412 $1.38 Million
Q2 2023

Aug 14, 2023

SELL
$8.8 - $13.4 $584,434 - $889,934
-66,413 Reduced 77.04%
19,788 $212,000
Q1 2023

May 12, 2023

BUY
$10.2 - $11.91 $166,994 - $194,990
16,372 Added 23.45%
86,201 $881,000
Q4 2022

Feb 10, 2023

BUY
$9.72 - $13.62 $67,359 - $94,386
6,930 Added 11.02%
69,829 $736,000
Q3 2022

Nov 14, 2022

BUY
$11.82 - $15.42 $404,563 - $527,780
34,227 Added 119.37%
62,899 $806,000
Q2 2022

Aug 12, 2022

SELL
$7.31 - $13.55 $122,522 - $227,111
-16,761 Reduced 36.89%
28,672 $367,000
Q1 2022

May 16, 2022

BUY
$10.47 - $16.75 $171,540 - $274,432
16,384 Added 56.4%
45,433 $475,000
Q4 2021

Feb 08, 2022

BUY
$15.36 - $25.0 $303,897 - $494,625
19,785 Added 213.57%
29,049 $448,000
Q3 2021

Nov 15, 2021

SELL
$22.56 - $29.68 $121,192 - $159,440
-5,372 Reduced 36.7%
9,264 $209,000
Q2 2021

Sep 13, 2021

BUY
$24.96 - $41.25 $365,314 - $603,735
14,636 New
14,636 $376,000

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $786M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.